Inhibition of STAT3 activation has shown promise in reducing glioma cell proliferation, inducing apoptosis, and inhibiting tumor invasion in preclinical models, potentially overcoming therapeutic resistance and improving patient outcomes [22,31,53,59,69,71,74,75,76,77]. This evidence concerns the gene STAT3 and neoplasm.